Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Correlation between outpatient opioid dosage and hospital visits in sickle cell disease patients

Elizabeth Minten, Kathryn Reynolds, Eldrida Randall et al. Nov 03, 2025 pp. 2962-2962 10.1182/blood-2025-2962

Abstract Introduction Sickle Cell Disease (SCD) is an autosomal recessive blood disorder caused by defective hemoglobin that leads to the “s...

Vitamin B6 deficiency: A cause of unexplained anemia in hospitalized patients in a tertiary care center

Kabeer Ali, Zehra Rahman, Walter Quan et al. Nov 03, 2025 pp. 4671-4671 10.1182/blood-2025-4671

Abstract Introduction: Anemia is a frequent clinical problem in hospitalized patients. While iron, vitamin B12, and folate deficiencies are...

Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma

Julia Wang, Chenchen Peng, Reyka Jayasinghe et al. Nov 03, 2025 pp. 5804-5804 10.1182/blood-2025-5804

Abstract Autologous chimeric antigen receptor (CAR) T-cell therapy has shown promise for relapsed/refractory multiple myeloma (MM), but dise...

Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia

Piyatida Chumnumsiriwath, Pongthep Vittayawacharin, Deepa Jeyakumar et al. Nov 03, 2025 pp. 2520-2520 10.1182/blood-2025-2520

Abstract Background: Allogeneic hematopoietic stem cell transplantation (AHSCT) plays a crucial role in the curative strategy for acute B-ce...

The improvement of renal function by complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria

Chengtao Qin, Yuemin Gong, Yawen Zhang et al. Nov 03, 2025 pp. 2892-2892 10.1182/blood-2025-2892

Abstract Background:Patients with paroxysmal nocturnal hemoglobinuria (PNH) experience chronic intravascular hemolysis due to the deficiency...

The bromodomain and extra-terminal domain protein BRD4 promotes both self renewal and inflammation in TET2 mutated clonal hematopoiesis

Alexander Marr, Madeline Halpin, Dominique Corbin et al. Nov 03, 2025 pp. 1398-1398 10.1182/blood-2025-1398

Abstract Progression of clonal hematopoiesis (CH) to myeloid neoplasms (MN) is highly dependent upon inflammatory signaling. The epigenetic...

Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study

Prof. Dr. Max S Topp, Guoqing Wang, Puja Patel et al. Nov 03, 2025 pp. 5480-5480 10.1182/blood-2025-5480

Abstract Introduction: DLBCL is a genetically heterogeneous malignancy that can be broadly categorized into 3 subtypes: activated B-cell–lik...

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation

Marcos de Lima, Gabriela Sanchez-Petitto, Edmund Waller et al. Nov 03, 2025 pp. 6086-6086 10.1182/blood-2025-6086

Abstract Background Allogeneic hematopoietic cell transplantation (allo-HCT) is an increasingly important curative option in adults with hig...

Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia

Satoshi Yoshimura, Yizhen Li, Xu Yang et al. Nov 03, 2025 pp. 5081-5081 10.1182/blood-2025-5081

Abstract Compared to B-cell acute lymphoblastic leukemia (ALL), treatment outcomes of T-ALL remain inferior, especially in relapsed or refra...

A retrospective analysis of fever incidence following vincristine administration in pediatric oncology patients

Zackery Gray, Tenley Lehman, Kirtana George et al. Nov 03, 2025 pp. 6842-6842 10.1182/blood-2025-6842

Abstract Background:Vincristine (VCR) is a commonly utilized chemotherapy agent for the treatment of pediatric cancers including leukemia, l...

The effect of bezuclastinib on the pathobiology of mastocytosis: Changes in BM mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal summit trial

Tracy George, Nathan Boggs, Jay Patel et al. Nov 03, 2025 pp. 1023-1023 10.1182/blood-2025-1023

Abstract Background: Systemic mastocytosis (SM) includes a spectrum of hematologic malignancies characterized by a variable degree of neopla...

Activated factor IX Ρadua delivered via adeno-associated virus enhances therapeutic efficacy in hemophilia B

Li Liu, Junjiang Sun, Timothy Nichols et al. Nov 03, 2025 pp. 4311-4311 10.1182/blood-2025-4311

Abstract Hemophilia B is a recessive X-linked bleeding disorder caused by a deficiency of coagulation factor IX (FIX), leading to trauma-ind...

Reproductive health care in a post-dobbs landscape for people with sickle cell disease: Clinical practices and challenges from hematologist perspectives

Preetha Nandi, Alyssa Kretz, Carolyn Sufrin et al. Nov 03, 2025 pp. 2595-2595 10.1182/blood-2025-2595

Abstract Introduction: The hematology community has recognized the potential impact of the 2022 Dobbs v. Jackson Women's...

Translational investigation of tolinapant (ASTX660) in Acute Myeloid Leukemia using integrated clinical, bioinformatic, and pharmacological approaches

Keli Lima, Frederico Lisboa Nogueira, Catarina Reis-Silva et al. Nov 03, 2025 pp. 2552-2552 10.1182/blood-2025-2552

Abstract Tolinapant (ASTX660) is an antagonist of the inhibitor of apoptosis proteins (IAPs) cIAP1 (BIRC2), cIAP2 (BIRC3), and XIAP. These I...

Cell cycle dependent and independent regulation of AKT activity in germinal center B-cell-like diffuse large B-cell lymphoma – a dual role of cyclin dependent kinase 2

Anezka Rajmonova, Kristyna Kupcova, Jana Senavova et al. Nov 03, 2025 pp. 3259-3259 10.1182/blood-2025-3259

Abstract Introduction. The PI3K/AKT (phosphatidylinositol 3-kinase / protein kinase B) pathway is one of the most frequently mutated and dere...

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Eliza Hawkes, Joanna Romejko-Jarosińska, Wojciech Jurczak et al. Nov 03, 2025 pp. 884-884 10.1182/blood-2025-884

Abstract Introduction: MCL is a rare B-cell non-Hodgkin lymphoma typically treated with first-line (1L) chemoimmunotherapy (CIT). While Brut...

Sex-and-ethnicity-related differences in primary central nervous system lymphoma based on the SEER database

Sajed Salem, Alexandre Matboui, Juba Sait et al. Nov 03, 2025 pp. 3669-3669 10.1182/blood-2025-3669

Abstract BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of Non-Hodgkin Lymphoma. Typically, PCNSL a...

The effect of recombinant factor VIIa treatment in non-traumatic intracranial hemorrhage: Systematic review and meta-analysis

Dalal Aldhafeeri, Mohammed Almakadi, Anila K N et al. Nov 03, 2025 pp. 6643-6643 10.1182/blood-2025-6643

Abstract Background: Intracerebral haemorrhage (ICH) is a devastating condition that can be life-threatening and can result in substantial f...

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Sylvain Garciaz, Louison Brac de La Perriere, Sarah Bertoli et al. Nov 03, 2025 pp. 5225-5225 10.1182/blood-2025-5225

Abstract Background Venetoclax (VEN) has transformed the management of patients (pts) with acute myeloid leukemia (AML)...

Endemic infections following CAR19-T-cell therapy: Real-life evidence in single-center in Brazil

Vanessa Bovolenta, Anita Cortez, Bianca Cal et al. Nov 03, 2025 pp. 7681-7681 10.1182/blood-2025-7681

Abstract Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is a promising treatment for refractory hematologic malignancies, bu...

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Hyun Yong Jin, Jeff Sharman, Luca Laurenti et al. Nov 03, 2025 pp. 682-682 10.1182/blood-2025-682

Abstract Background: Venetoclax + an anti-CD20 antibody has shown deep remissions and long-term immune recovery in patients (pts) with relap...

GWAS-guided pharmacogenomic risk scores predict premedication-related pegaspargase hypersensitivity and toxicities in pediatric and adolescent young adults with acute lymphoblastic leukemia or lymphoma

Vivek Shastri, Sonia Morales, Anurag Agrawal et al. Nov 03, 2025 pp. 6881-6881 10.1182/blood-2025-6881

Abstract Background: The addition of asparaginase to chemotherapy regimens has played a key role in significantly improving outcomes in pedi...

Vitamin B12 drives epigenetic reprogramming and leukemia progression through metabolic rewiring in AML

Peter Lyon, John Brabson, Yoon Sing Yap et al. Nov 03, 2025 pp. 3250-3250 10.1182/blood-2025-3250

Abstract Introduction: Large population studies have shown that elevated vitamin B12 serum levels are associated with increased all-cause mo...

Arterial thrombotic events in lymphoma patients: Systematic review and meta-analysis

Tamara Bibic, Vojin Vukovic, Jelena Ivanovic et al. Nov 03, 2025 pp. 4904-4904 10.1182/blood-2025-4904

Abstract Introduction: Arterial thrombotic events (ATE) represent a serious but underreported complication in lymphoma patients, potentially...

Emicizumab for severe von willebrand disease (VWD): The (EmiVWD) study enrollment 2025

Jonathan Roberts, May Chien, Sweta Gupta et al. Nov 03, 2025 pp. 1315-1315 10.1182/blood-2025-1315

Abstract Background and Significance: Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1-1% of...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page